What it's for (Indications)
- Norethisterone oenanthate is primarily indicated for long-acting reversible contraception (LARC) in women.
- It is administered as an intramuscular injection to prevent pregnancy.
- Its efficacy stems from its potent progestational effects, which include the suppression of ovulation, rendering it a highly effective contraceptive method when administered correctly and consistently.
- This formulation offers a convenient and discreet option for contraception, particularly suitable for women who prefer a non-daily or non-weekly method, or those for whom estrogen-containing contraceptives are contraindicated due to specific medical conditions such as a history of venous thromboembolism, severe hypertension, or certain types of migraines.
- It is used as a stand-alone progestogen-only contraceptive.
- The duration of action after a single injection typically provides contraceptive efficacy for up to 8 weeks, making adherence less demanding than daily oral pills.
- It is chosen by many women due to its high efficacy and ease of use, contributing significantly to family planning initiatives globally, and can be a suitable option during lactation after appropriate post-partum intervals.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The typical recommended dosage for norethisterone oenanthate (e.g., Norigest) as an intramuscular contraceptive is 200 mg administered as a deep intramuscular injection every 8 weeks. The first injection should ideally be given during the first 5 days of a menstrual cycle to ensure immediate contraceptive protection, although it can be initiated at other times with appropriate backup contraception. If switching from another hormonal contraceptive method, timing should align with the previous method's schedule to ensure continuous protection. For post-partum women who are not breastfeeding, the injection can be given immediately, or within 21 days post-partum. If given later than 21 days post-partum, additional barrier methods should be used for the first 7 days following the injection. For breastfeeding women, the initiation is generally advised after 6 weeks post-partum to avoid potential effects on the infant or milk supply, though this can vary by national guidelines and individual clinical assessment. Consistent adherence to the 8-week injection schedule is crucial for maintaining optimal contraceptive efficacy. |
Safety & Warnings
Common Side Effects
- Patients using norethisterone oenanthate may experience a wide range of side effects, primarily related to its progestogenic activity.
- The most common side effects involve menstrual irregularities, including unpredictable bleeding patterns, prolonged bleeding, spotting, or, conversely, amenorrhea (absence of menstruation), which can be distressing for some users but is often considered a non-harmful effect.
- Other frequently reported systemic side effects include weight changes (gain or, less commonly, loss), headaches, dizziness, nausea, abdominal discomfort, and breast tenderness or enlargement.
- Mood changes, encompassing depression, anxiety, and irritability, are also observed and warrant careful monitoring, especially in patients with a history of mood disorders.
- Acne and changes in hair growth (e.
- g.
- , hirsutism or hair loss) can occur.
- Injection site reactions, such as pain, bruising, redness, or induration, are common but usually mild and transient.
- Less common but serious potential side effects include a decrease in bone mineral density with long-term use, particularly in adolescents and young adults, and a potential for a delayed return to fertility after discontinuation.
- While generally lower than with combined oral contraceptives, there is also a very small theoretical risk of venous thromboembolism.
Serious Warnings
- Black Box Warning: BLACK BOX WARNING: SERIOUS WARNINGS REGARDING BONE MINERAL DENSITY LOSS AND DELAYED RETURN TO FERTILITY. Norethisterone oenanthate, as a long-acting progestogen-only contraceptive, is associated with significant warnings that warrant careful consideration and comprehensive patient counseling before initiation. 1. BONE MINERAL DENSITY (BMD) LOSS: Prolonged use of norethisterone oenanthate has been associated with a significant decrease in bone mineral density, particularly in adolescents and young adults who are still accumulating bone mass. The clinical significance of this bone loss during later life, including its impact on the risk of osteoporotic fractures, has not been fully established, and the complete reversibility of bone mineral loss after discontinuation of norethisterone oenanthate is uncertain. Prescribers should weigh the benefits of norethisterone oenanthate against this potential risk, especially in adolescents and young women, and consider alternative contraceptive methods in patients with significant risk factors for osteoporosis (e.g., a history of anorexia nervosa, chronic corticosteroid use, significant alcohol or tobacco use, or other conditions affecting bone metabolism). Adequate calcium and vitamin D intake should be encouraged. 2. DELAYED RETURN TO FERTILITY: Patients should be thoroughly counselled regarding the potential for a delayed return to fertility after discontinuation of norethisterone oenanthate. While most women eventually conceive, the return to ovulation and subsequent fertility can range from several months up to a year or more following the last injection. This information is critical for patients planning future pregnancies. 3. OTHER SERIOUS CONSIDERATIONS: Although lower than with combined hormonal contraceptives, a very small risk of venous thromboembolism (VTE) exists. Pregnancy must be excluded before each injection. All patients should be thoroughly assessed for contraindications and monitored for potential adverse effects.
- Several important warnings are associated with the use of norethisterone oenanthate beyond the severe risks outlined in the Black Box Warning section.
- Clinicians should be vigilant for the development or worsening of depression, and patients with a history of depression should be carefully monitored.
- The possibility of ectopic pregnancy should always be considered in women presenting with lower abdominal pain or amenorrhea while using this contraceptive, particularly if they have risk factors for ectopic pregnancy.
- Although generally well-tolerated, some women may experience fluid retention, which could be clinically significant for patients with pre-existing conditions sensitive to fluid balance, such as cardiac or renal dysfunction.
- Changes in glucose tolerance may occur, necessitating careful monitoring in diabetic patients or those at risk of diabetes.
- Liver function should be assessed if jaundice develops, if pruritus persists, or if liver function tests become abnormal, and the medication should be discontinued if severe impairment is detected.
- Patients should be thoroughly informed about the highly altered bleeding patterns, which are very common and can include irregular bleeding, spotting, or complete amenorrhea; they should be reassured that these changes are generally not indicative of a serious underlying pathology but warrant investigation if persistent, heavy, or unusual.
- Regular follow-up appointments are essential to monitor for adverse effects, assess bone mineral density if long-term use is anticipated, and ensure continued suitability of the contraceptive method.
How it Works (Mechanism of Action)
Norethisterone oenanthate is a synthetic progestogen that functions as a highly effective contraceptive primarily through three distinct and synergistic mechanisms of action. Firstly, and most crucially, it exerts a potent inhibitory effect on the hypothalamic-pituitary-ovarian axis, leading to the suppression of ovulation. This is achieved by inhibiting the pulsatile release of Gonadotropin-Releasing Hormone (GnRH), which in turn prevents the surge of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH) necessary for follicular development and ovum release. Secondly, it induces significant changes in the cervical mucus, increasing its viscosity and reducing its quantity, thereby making it thick, sparse, and hostile to sperm penetration. This physical barrier effectively impedes the passage of sperm into the upper genital tract, preventing them from reaching the ovum. Thirdly, it causes endometrial atrophy, thinning the uterine lining and making it unfavorable for implantation should fertilization occur, although this is considered a secondary mechanism given the primary anovulatory effect. The oenanthate ester prolongs the duration of action by slowly releasing norethisterone, which is then metabolized to active norethisterone, maintaining sustained progestogenic effects over an extended period, typically around 8 weeks. These combined actions ensure a high level of contraceptive efficacy.